Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions
- 30 October 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (22) , 9114-9141
Abstract
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social communication and interaction, and restricted, repetitive patterns of behaviour, interests and activities. Various factors are involved in the etiopathogenesis of ASD, including genetic factors, environmental toxins and stressors, impaired immune responses, mitochondrial dysfunction, neuroinflammation. The heterogeneity in the phenotype among ASD patients and the complex etiology of the condition have long impeded the advancement of the development of pharmacological therapies. In the recent years, the integration of findings from mouse models to human genetics resulted in considerable progress towards the understanding of ASD pathophysiology. Currently, strategies to treat core symptoms of ASD are directed to correct synaptic dysfunctions, abnormalities in central oxytocin, vasopressin, and serotonin neurotransmission, and neuroinflammation. Here, we present a survey of the studies that have suggested molecular targets for drug development for ASD and the state-of-the-art of medicinal chemistry efforts in related areas.Keywords
This publication has 255 references indexed in Scilit:
- The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in ratsPsychopharmacology, 2011
- TSC1/TSC2 signaling in the CNSFEBS Letters, 2011
- Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disordersPharmacology & Therapeutics, 2011
- Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activityNeuroscience, 2010
- Synapse Pathology in Psychiatric and Neurologic DiseaseCurrent Neurology and Neuroscience Reports, 2010
- The Challenge of Translation in Social Neuroscience: A Review of Oxytocin, Vasopressin, and Affiliative BehaviorNeuron, 2010
- Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of Fragile X syndromeBiochemical Pharmacology, 2010
- Autism: Many Genes, Common Pathways?Cell, 2008
- Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicityGlia, 2008
- Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO miceNeurobiology of Disease, 2008